Belvedere Trading
DFTX

Belvedere Trading’s Definium Therapeutics DFTX Stock Holding History

Belvedere Trading’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,307
Closed -$130K – 560
2021
Q4 		$130K Sell
9,307
-5,413
-37% -$173K 0.01% 265
2021
Q3 		$506K Buy
+14,720
New +$636K 0.01% 115

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Belvedere Trading's DFTX Position: Q1 2022 in Review

Belvedere Trading sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 1,269 shares — an estimated $18K sold.

Belvedere Trading first reported a position in DFTX in Q2 2021 and held it in 3 quarters. The position peaked at $582K in Q2 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

  • Belvedere Trading reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Belvedere Trading sold 1,269 Definium Therapeutics shares in Q1 2022, an estimated $18K.
  • Belvedere Trading first reported a position in Definium Therapeutics in Q2 2021 and held it in 3 quarters.
  • Belvedere Trading's Definium Therapeutics position peaked at $582K in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on Belvedere Trading's 13F filing for Q1 2022, filed 20 Apr 2022.